Document is current
Any future updates will be listed below
-
Authors
Giraldo, Nicolas A.
Nguyen, Peter
Engle, Elizabeth L.
Kaunitz, Genevieve J.
Cottrell, Tricia R.
Berry, Sneha
Green, Benjamin
Soni, Abha
Cuda, Jonathan D.
Stein, Julie E.
Sunshine, Joel C.
Succaria, Farah
Xu, Haiying
Ogurtsova, Aleksandra
Danilova, Ludmila
Church, Candice D.
Miller, Natalie J.
Fling, Steve
Lundgren, Lisa
Ramchurren, Nirasha
Yearley, Jennifer H.
Lipson, Evan J.
Cheever, Mac
Anders, Robert A.
Nghiem, Paul T.
Topalian, Suzanne L.
Taube, Janis M. https://orcid.org/0000-0002-8273-4395
-
Funding
Funding for this research was provided by:
Melanoma Research Alliance
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
National Cancer Institute (R01 CA142779, K24 CA139052)
National Institutes of Health (T32 CA193145, UM1 CA154967, IH/NCI Cancer Center Support Grant P30 CA015704)
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Cancer Immunotherapy Trials Network
Stand Up To Cancer–Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012)
- License Information
-
More Information
Article History
Received: 21 June 2018
Accepted: 6 September 2018
First Online: 1 October 2018
Ethics approval and consent to participate
: Evaluation of archived pathology specimens described in this manuscript is covered under a study approved by the Johns Hopkins University Institutional Review Board which does not require individual patient consent.
: Not applicable.
: EJL: consultant for Bristol-Myers Squibb, EMD Serono, Merck, Novartis; research funding from Bristol-Myers Squibb.RAA: Bristol-Myers Squibb, Merck, Five Prime Therapeutics, Adaptive Biotechnologies.SLT: consultant for Five Prime Therapeutics; stock options from Five Prime Therapeutics; research funding from Bristol-Myers Squibb.JMT: consultant for Bristol-Myers Squibb, Amgen, Merck, AstraZeneca; research funding from Bristol-Myers Squibb
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
